Eyenovia Inc. (EYEN) shares surged on Monday after the company announced the launch of a new FDA-approved ophthalmic drug, APP13007, developed in collaboration with Formosa Pharmaceuticals. This innovative drug, the first of its kind using clobetasol propionate, offers a convenient and cost-effective treatment for postoperative inflammation and pain following eye surgery.
Results for: Eyenovia
Eyenovia Inc. (EYEN) stock is trading higher on Thursday after a significant drop on Wednesday, following the company’s announcement of a $5.14 million share offering. The funds will be used for commercialization, clinical studies, and general corporate purposes.